Jane Street Group LLC Sells 5,160 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX)

Jane Street Group LLC cut its holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 5.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 93,876 shares of the company’s stock after selling 5,160 shares during the period. Jane Street Group LLC’s holdings in TScan Therapeutics were worth $468,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Great Point Partners LLC lifted its stake in TScan Therapeutics by 8.0% in the third quarter. Great Point Partners LLC now owns 1,016,375 shares of the company’s stock worth $5,062,000 after purchasing an additional 75,544 shares during the last quarter. Checkpoint Capital L.P. bought a new stake in TScan Therapeutics in the third quarter worth $4,110,000. State Street Corp lifted its stake in TScan Therapeutics by 24.4% in the third quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after purchasing an additional 148,414 shares during the last quarter. abrdn plc raised its stake in shares of TScan Therapeutics by 27.2% during the third quarter. abrdn plc now owns 371,655 shares of the company’s stock valued at $1,851,000 after acquiring an additional 79,511 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of TScan Therapeutics by 60.8% during the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock valued at $1,799,000 after acquiring an additional 116,316 shares during the last quarter. 82.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on TCRX shares. Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective on shares of TScan Therapeutics in a research note on Monday, December 23rd. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a research note on Wednesday, December 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Wednesday, December 11th.

TScan Therapeutics Price Performance

TCRX stock opened at $2.98 on Tuesday. TScan Therapeutics, Inc. has a 1 year low of $2.60 and a 1 year high of $9.69. The company has a market cap of $159.05 million, a P/E ratio of -2.81 and a beta of 0.91. The firm has a 50-day moving average of $4.08 and a 200 day moving average of $5.25. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.86 million. On average, sell-side analysts forecast that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.